Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (LLY)
NYSE:LLY
Holding LLY?
Track your performance easily
LLY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$561.65 - $972.53
Previous Close$818.93
Volume5.27M
Average Volume (3M)3.18M
Market Cap
$777.42B
Enterprise Value$805.11B
Total Cash (Recent Filing)$3.52B
Total Debt (Recent Filing)$31.12B
Price to Earnings (P/E)89.6
Beta0.53
Next Earnings
Jan 30, 2025EPS Estimate
$5.46Next Dividend Ex-Date
Nov 15, 2024Dividend Yield0.61%
Share Statistics
EPS (TTM)9.14
Shares Outstanding949,315,694
10 Day Avg. Volume4,452,433
30 Day Avg. Volume3,181,498
Standard Deviation0.09
R-Squared0.06
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)54.59
Price to Sales (P/S)19.02
Price to Cash Flow (P/CF)52.40
P/FCF Ratio82.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue19.70
Enterprise Value/Gross Profit29.77
Enterprise Value/Ebitda67.56
Forecast
1Y Price Target
$1,044.50Price Target Upside27.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Eli Lilly & Co News
Bulls Say, Bears Say
Bulls Say
Alzheimer's And New TreatmentsLilly continues to make progress in Alzheimer’s, expecting sBLA submission for the Kisunla new dosing regimen.
Market Expansion And Economic StudiesThe UK plans to evaluate tirzepatide’s potential to reduce the economic burden of obesity, with a significant investment and collaboration with the University of Manchester.
Product Launch And Market PositionLLY's parenteral manufacturing moat and Orforg's upcoming launch puts LLY in the best position to capitalize on the still large Diabesity TAM.
Bears Say
Product CompetitionCompetition is looming with companies like ZEAL, VKTX, GPCR, and Roche posing potential threats.
Revenue And EarningsLLY reported a miss driven by Mounjaro & Zepbound weakness, with a significant shortfall in their expected revenue.
Revenue GuidanceLLY lowered the top end of its revenue guidance, indicating potential challenges in meeting previous expectations.
---
Ownership Overview
10.35% Insiders
23.14% Mutual Funds
12.50% Other Institutional Investors
37.90% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LLY FAQ
What was Eli Lilly & Co’s price range in the past 12 months?
Eli Lilly & Co lowest stock price was $561.65 and its highest was $972.53 in the past 12 months.
What is Eli Lilly & Co’s market cap?
Currently, no data Available
When is Eli Lilly & Co’s upcoming earnings report date?
Eli Lilly & Co’s upcoming earnings report date is Jan 30, 2025 which is in 87 days.
How were Eli Lilly & Co’s earnings last quarter?
Eli Lilly & Co released its earnings results on Oct 30, 2024. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.405 by -$0.225.
Is Eli Lilly & Co overvalued?
According to Wall Street analysts Eli Lilly & Co’s price is currently Undervalued.
Does Eli Lilly & Co pay dividends?
Eli Lilly & Co pays a Quarterly dividend of $1.3 which represents an annual dividend yield of 0.61%. See more information on Eli Lilly & Co dividends here
What is Eli Lilly & Co’s EPS estimate?
Eli Lilly & Co’s EPS estimate is $5.46.
How many shares outstanding does Eli Lilly & Co have?
Eli Lilly & Co has 949,315,700 shares outstanding.
What happened to Eli Lilly & Co’s price movement after its last earnings report?
Eli Lilly & Co reported an EPS of $1.18 in its last earnings report, missing expectations of $1.405. Following the earnings report the stock price went down -6.281%.
Which hedge fund is a major shareholder of Eli Lilly & Co?
Among the largest hedge funds holding Eli Lilly & Co’s share is PRIMECAP Management Co. It holds Eli Lilly & Co’s shares valued at 18B.
---
Eli Lilly & Co Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,044.50 (27.54% Upside)
$1,044.50 (27.54% Upside)
Blogger Sentiment
Bullish
LLY Sentiment 85%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $50.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Bearish
Bullish news 20%
Bearish news 80%
Bearish news 80%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.69%
12-Months-Change
Fundamentals
Return on Equity
65.75%
Trailing 12-Months
Asset Growth
30.55%
Trailing 12-Months
Company Description
Eli Lilly & Co
Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana.
---
LLY Company Deck
---
LLY Earnings Call
Q3 2024
0:00 / 0:00
---
LLY Revenue Breakdown
84.44% Net product revenue
15.56% Collaboration and other revenue
---
LLY Stock 12 Month Forecast
Average Price Target
$1,044.50
▲(27.54% Upside)
Technical Analysis
Best Analysts Covering LLY
1 Year
1 Year Success Rate
34/38 ratings generated profit
1 Year Average Return
+36.62%
reiterated a buy rating last month
Copying Louise Chen's trades and holding each position for 1 Year would result in 89.47% of your transactions generating a profit, with an average return of +36.62% per trade.
---